SALIX PHARMACEUTICALS LTD DEL
SLXP
SLXP was delisted on the 31st of March, 2015.
348 hedge funds and large institutions have $10.6B invested in SALIX PHARMACEUTICALS LTD DEL in 2014 Q3 according to their latest regulatory filings, with 81 funds opening new positions, 102 increasing their positions, 146 reducing their positions, and 38 closing their positions.
113% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 38
111% more funds holding in top 10
Funds holding in top 10: 9 → 19 (+10)
28% more capital invested
Capital invested by funds: $8.26B → $10.6B (+$2.3B)
13% more funds holding
Funds holding: 308 → 348 (+40)
27% less call options, than puts
Call options by funds: $346M | Put options by funds: $477M
30% less repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 146
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$290M |
| 2 |
YCMGA
York Capital Management Global Advisors
New York
|
+$131M |
| 3 |
SIG
Senator Investment Group
New York
|
+$109M |
| 4 |
SC
Sculptor Capital
New York
|
+$90.8M |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
+$86.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$215M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$183M |
| 3 |
Bank of New York Mellon
New York
|
-$144M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
-$107M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$101M |
SLXP Hedge Fund Activity: Q3 2014 in Review
348 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in SALIX PHARMACEUTICALS LTD DEL (SLXP) for Q3 2014, worth a combined $10.6B — up 28% from $8.26B a quarter earlier.
Buyers outnumbered sellers: 81 funds opened new SLXP positions and 38 closed out — a net gain of 43 holders — while 102 added to existing stakes and 146 trimmed.
The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $290M. The largest seller was Wellington Management Group, cutting an estimated $215M.
- 348 institutional investors held SALIX PHARMACEUTICALS LTD DEL (SLXP) as of Q3 2014, up from 308 in Q2 2014.
- Funds reported $10.6B of SALIX PHARMACEUTICALS LTD DEL stock for Q3 2014, up 28% quarter-over-quarter.
- 81 funds opened new SALIX PHARMACEUTICALS LTD DEL positions in Q3 2014 and 38 closed out, a net change of +43 holders.
- The largest SALIX PHARMACEUTICALS LTD DEL buyer in Q3 2014 was Pentwater Capital Management, an estimated $290M added.
- The largest SALIX PHARMACEUTICALS LTD DEL seller in Q3 2014 was Wellington Management Group, an estimated $215M sold.
Based on aggregated 13F filings for Q3 2014.